Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
- Transaction Price: $39.00 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interests following the re-investment of dividends paid on January 8, 2009.
- Participants: Mr. E J Gray (14.65 ADRs) and Mr. D J Phelan (444.00 ADRs).
Material Changes
No material changes to financial performance or operational status are reported in this filing. The only change noted is the increase in shareholdings for the named individuals due to dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the dividend reinvestment mechanism for the SmithKline Beecham Mid-Term Incentive Plan.
- Confirm the share price of $39.00 per ADR on the transaction date.
- Note that this filing does not contain quarterly or annual financial results.